Comparative Pharmacology
Head-to-head clinical analysis: METASTRON versus MPI INDIUM DTPA IN 111.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METASTRON versus MPI INDIUM DTPA IN 111.
METASTRON vs MPI INDIUM DTPA IN 111
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
Indium In-111 DTPA is a radiopharmaceutical that emits gamma radiation, used for imaging. DTPA chelates indium-111 and, after administration, distributes in the extracellular fluid and is cleared by glomerular filtration, allowing cisternography and renal imaging.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
Adult: 18.5 MBq (0.5 mCi) administered intravenously as a single dose for renal imaging.
None Documented
None Documented
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Terminal half-life: 2.5-4.0 hours (plasma); prolonged in renal impairment.
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Renal: 90% within 24 hours via glomerular filtration; minimal biliary/fecal (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical